Phaseline

Companies › Genascence

Genascence: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Immunology; next expected readout May 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
GNSC-001
AAV2.5-mediated IL-1Ra gene therapy
IL1Phase 1Osteoarthritis, KneeMay 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05835895GNSC-001Phase 1Osteoarthritis, KneeImmunologyMay 2029

Targets

IL1 (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.